Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

BACKGROUND: Lapatinib is the human epidermal growth factor receptor 2 (HER2) targeting agent approved globally for HER2-positive metastatic breast cancer (MBC). The efficacy, safety and pharmacokinetics (PK) of lapatinib combined with paclitaxel (L+P) were investigated in this study, to establish cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kenichi, Kuroi, Katsumasa, Shimizu, Satoru, Rai, Yoshiaki, Aogi, Kenjiro, Masuda, Norikazu, Nakayama, Takahiro, Iwata, Hiroji, Nishimura, Yuichiro, Armour, Alison, Sasaki, Yasutsuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666271/
https://www.ncbi.nlm.nih.gov/pubmed/25967286
http://dx.doi.org/10.1007/s10147-015-0832-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666271/
https://www.ncbi.nlm.nih.gov/pubmed/25967286
http://dx.doi.org/10.1007/s10147-015-0832-5

Ejemplares similares